Investors - Media Releases

Stay Informed

2010 2009 2008 2007 2006 2005 2004 2003

Back to list

March 31, 2010

mondoBIOTECH holding AG (SIX: RARE): Results 2009

Stans, 31 March 2010. mondoBIOTECH holding AG (SIX: RARE) announces today its financial results 2009. General Overview The Group generated operating revenues of CHF 13.74 million in the year ending 31 December 2009 (2008: CHF 14.54 million), mainly from clinical development services related to our licensing agreements, against operating expenses of CHF 25.84 million (2008: CHF 23.71 million) for the same period, 78% of which was derived from research and development activities. The loss of the period is CHF 12.21 million (2008: CHF 9.40 million), representing a basic and diluted loss per Common Share of CHF 1.868 (2008: basic and diluted loss of CHF 1.459) and a basic and diluted loss per Voting Right Share of CHF 0.186 (2008: basic and diluted loss of CHF 0.145). Over the two years 2008 and 2009, the Group generated operating revenues of CHF 28.28 million, against operating expenses of CHF 49.56 million for the same period. The Group raised net proceeds of CHF 13.85 million from private placements of new shares during the same period, and on 31 December 2009 the balance sheet showed CHF 4.63 million of cash and cash equivalents. On 17 February 2010, the Company closed a round of fundraising by issuing 79’134 new Common Shares from its authorized share capital for a gross contribution of about CHF 8.70 million. As a part of this round of fundraising, the Company closed an option program for shareholders by issuing 11’141 call options at a unit price of CHF 40, giving the holder the right to purchase one Common Share out of the conditional share capital within an option period of three years ending 22 February 2013 at a strike price of CHF 150 per option. The net proceeds from this option program were about CHF 0.44 million. If executed, the outstanding call options will generate gross proceeds until 22 February 2013 of approximately CHF 1.67 million. The Group has sufficient cash and cash equivalents necessary to finance its actual level of activities for at least twelve months. The operating activities for 2010 will increasingly focus on optimizing the potential value of the pipeline, i.e. the commercialization of medicinal product candidates at their actual development stage and the collaboration with partners with regards to licensed medicinal product candidates. This concentration will benefit the Group by leading to an overall cost reduction. Nevertheless, to continue its growth strategy and to maximize the potential value of its pipeline by accelerating the development of the highest possible number of medicinal product candidates, mondoBIOTECH’s envisions increasing its share capital by frequently issuing new shares. mondoBIOTECH intends to issue such new shares to existing shareholders, new investors and/or individuals and entities which are directly or indirectly affected by and/or directly or indirectly involved in the treatment of rare and neglected diseases. Revenues Revenues of CHF 13.74 million in 2009 refer to CHF 13.13 million spent on the performance of clinical development services (mainly project management and intellectual property services) under the operating segment ‘Development Services’ and to CHF 0.61 million for milestones from licensing agreements under the operating segment ‘Projects’. The revenues in 2008 refer to CHF 14.54 million generated exclusively under the ‘Development Services' segment. The increase in revenues from licensing relates to a licensing agreement and to an agreement to co-license, both signed in 2009. We expect the agreements to co-license – in which a counterparty will have the right to a portion of future sign-up fees, milestones and royalties – will anticipate potential future cash flows from which we might eventually realize part of the economic potential of our medicinal product candidates. The decrease in revenues from development services relates to the termination, during the last quarter 2009, of clinical phase II services supplied to third parties on one of our out licensed medicinal product candidates. Research and development Research and development expenses decreased from CHF 20.17 million in 2008 to CHF 20.14 million in 2009, of which CHF 9.03 million refers to services acquired for providing development services (with a reduction in respect to 2008 of CHF 0.15 million due to the termination of the clinical phase II trial previously mentioned), CHF 1.57 refers to services acquired for improving the development status of our pipeline, mainly driven by intellectual property services (with a reduction of CHF 1.11 in respect of 2008 due to economies of scale and rationalization effects) and CHF 9.54 refers to fixed costs including employee benefit expenses, information technology, space and structures, and non monetary costs components (depreciation, amortization and impairments), with an increase of CHF 1.18 in respect of 2008 mainly due to impairment charges on assets recognized during 2009. Sales and marketing Sales and marketing expenses increased from CHF 2.35 million in 2008 to CHF 3.63 million in 2009. The increase is due to an increase in the marketing services acquired, including sponsorships (0.26 million) and to a general increase in the fixed costs mainly driven by travel expenses and non monetary costs components, in particular impairment charges on assets recognized during 2009. Management and administration Management and administration expenses were CHF 2.07 million in 2009 against CHF 1.19 million in 2008. The increase of CHF 0.88 million is principally due to the variable part of such expenses, in particular legal services in connection with the various operations performed on the equity structure of the Company in the first half of 2009, to the listing at the SIX Swiss Exchange on August 2009 and to the preparation of the share capital increase performed during the first two month of 2010. The annual report 2009 is available under www.mondobiotech.com/Investors/All_Reports.cfm For more information please contact: mondoBIOTECH holding AG Patrick Pozzorini, CFO Mürgstrasse 18 CH-6370 - Stans T   +41 (0)840 200 010 F   +41 (0)840 200 011 investor@mondobiotech.com www.mondobiotech.com About Mondobiotech mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases. Disclaimer The foregoing release may contain forward-looking statements. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. Mondobiotech Holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. ANY NON-COMPLIANCE WITH SUCH RESTRICTIONS MAY RESULT IN AN INFRINGEMENT OF U.S. SECURITIES LAWS. SECURITIES OF MONDOBIOTECH HOLDING AG ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF MONDOBIOTECH HOLDING AG HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT THE REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES LAWS. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO ART. 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR ART. 27 ET SEQ. OF THE SIX LISTING RULES. Personal Information This email is from mondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your system. Download the Newsletter in pdf format

Back to list